Certara, Inc. Announces Update of D360 Scientific Informatics Software
November 29, 2021 at 04:30 pm EST
Share
Certara, Inc. announced the release of D360 version 21.5, an industry-leading scientific informatics software for discovery scientists to integrate many data sources and analyze small molecules and biologic drugs for fast, high-confidence go/no-go decisions. This latest release increases research efficiency with comprehensive data analysis, enhanced workflows and data handling, and innovative visualization capabilities. Certara?s D360 scientific informatics software is used globally by more than 6,000 discovery research scientists at biopharmaceutical and biotechnology companies, including five of the top 10 by research and development spend. The D360 software delivers end-to-end access to data and integrated scientific intelligence, resulting in timelier insights and greater understanding of drug candidates. New capabilities of Certara?s D360 software include: Biologic drugs: Support for visual sequence clustering and HELM (Hierarchical Editing Language for Macromolecules) version 2, which is widely adopted across the industry, and enhanced capabilities for sequence-activity relationship generation; Small molecules: Transformation analysis, which allows scientists to understand the effect of structural changes over a range of assays and properties; Workflows: Accelerated scientific decision-making using filter capabilities and multi-valued data fields; Data visualization: Visualization of multi-parameter project progression and new details viewer mode for focus on specific aspects of a dataset to accelerate scientific workflows.
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development in the global biopharmaceutical industry. It is focused on producing medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include life sciences companies of all sizes along with contract research organizations, academic institutions, and global regulators. Its software and service are used by approximately 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, Egypt, and the United Kingdom.